Unknown

Dataset Information

0

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer.


ABSTRACT: CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in a series of 6035 early-stage invasive primary breast cancers. CINSARC had independent prognostic value in the Luminal B subtype and not in the other subtypes. In Luminal B patients receiving adjuvant endocrine therapy but no chemotherapy, CINSARC identified patients with different 5-year DFS (90% [95%CI 86-95] in low-risk vs. 79% [95%CI 75-84] in high-risk, p = 1.04E-02). Luminal B CINSARC high-risk tumors were predicted to be less sensitive to endocrine therapy and CDK4/6 inhibitors, but more vulnerable to homologous recombination targeting and immunotherapy. We concluded that CINSARC adds prognostic information to that of clinicopathological features in Luminal B breast cancers, which might improve patients' stratification and better orient adjuvant treatment. Moreover, it identifies potential therapeutic avenues in this aggressive molecular subtype.

SUBMITTER: Goncalves A 

PROVIDER: S-EPMC8099860 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC2662705 | biostudies-literature
2021-12-19 | PXD028335 | Pride
| S-EPMC8553750 | biostudies-literature
| S-EPMC8299666 | biostudies-literature
| S-EPMC3206152 | biostudies-literature
| S-EPMC5928887 | biostudies-literature
| S-EPMC2500166 | biostudies-literature
| S-EPMC3446385 | biostudies-literature
| S-EPMC7976380 | biostudies-literature
| S-EPMC10859882 | biostudies-literature